Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed, clinical guidelines on psoriasis ...

Skyrizi is approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AbbVie said the annual wholesale cost for maintenance dosing of ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

"Skyrizi has the potential to help psoriasis patients achieve high rates of skin clearance, bringing them closer to reaching long-term treatment goals with every 12-week dosing." AbbVie hopes for ...

relative to quarterly Skyrizi maintenance dosing,” the analysts added in a March 10 note. The clinical wins didn't end with psoriasis either. Monday morning, J&J also announced that icotrokinra ...

People taking Skyrizi in clinical trials didn’t report having depression. However, it’s important to note that plaque psoriasis and depression may have links. (Skyrizi is approved to treat ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

For one, ESK-001 is safe and can be valuable to patients, he said, and the drug stacks up competitively against a pantheon of psoriasis treatments that includes AbbVie Inc.'s injectable Skyrizi ...

Medscape Medical News, August 08, 2019 Alert PRAC Proposes New Measures to Avoid Methotrexate Dosing Errors The ... Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis The interleukin-23 ...